Human equilibrative nucleoside transporter 1 (hENT1) levels predict response to gemcitabine in patients with biliary tract cancer (BTC).

Human equilibrative nucleoside transporter 1 (hENT1) levels predict response to gemcitabine in patients with biliary tract cancer (BTC).

Item
http://www.wikidata.org/entity/Q37767728
How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusionPlasma membrane transporters in modern liver pharmacologyhENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: a systematic reviewFinding novel pharmaceuticals in the systems biology era using multiple effective drug targets, phenotypic screening and knowledge of transporters: where drug discovery went wrong and how to fix it.Gemcitabine sensitivity factors, hENT1 and RRM1 as potential prognostic biomarker for advanced biliary tract cancer.Nucleoside transporter proteins as biomarkers of drug responsiveness and drug targets.Enhancing Drug Efficacy and Therapeutic Index through Cheminformatics-Based Selection of Small Molecule Binary Weapons That Improve Transporter-Mediated Targeting: A Cytotoxicity System Based on Gemcitabine.Membrane Localization of Human Equilibrative Nucleoside Transporter 1 in Tumor Cells May Predict Response to Adjuvant Gemcitabine in Resected Cholangiocarcinoma PatientsPrognostic predictive values of gemcitabine sensitivity-related gene products for unresectable or recurrent biliary tract cancer treated with gemcitabine alone.A meta-analysis of gemcitabine biomarkers in patients with pancreaticobiliary cancers.Sclareolide enhances gemcitabine‑induced cell death through mediating the NICD and Gli1 pathways in gemcitabine‑resistant human pancreatic cancer.Nucleoside analogs: ready to enter the era of precision medicine?Novel regulation of equlibrative nucleoside transporter 1 (ENT1) by receptor-stimulated Ca2+-dependent calmodulin binding.Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy.Role of drug-dependent transporter modulation on the chemosensitivity of cholangiocarcinoma.Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma.On the design principles of peptide-drug conjugates for targeted drug delivery to the malignant tumor site.
P2860

Human equilibrative nucleoside transporter 1 (hENT1) levels predict response to gemcitabine in patients with biliary tract cancer (BTC).

Item
http://www.wikidata.org/entity/Q37767728
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Human equilibrative nucleoside ...... th biliary tract cancer (BTC).
@en
Human equilibrative nucleoside transporter 1
@nl
type
label
Human equilibrative nucleoside ...... th biliary tract cancer (BTC).
@en
Human equilibrative nucleoside transporter 1
@nl
prefLabel
Human equilibrative nucleoside ...... th biliary tract cancer (BTC).
@en
Human equilibrative nucleoside transporter 1
@nl
P1433
P1476
P2093
P304
P31
P356
P433
P478
P50
P577
P698
P356
P1433
P1476
Human equilibrative nucleoside ...... ith biliary tract cancer (BTC)
@en
P2093
P304
P31
P356
10.2174/156800911793743600
P433
P478
P50
P577
P698